Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

HER2-positive breast cancer

Onco_background

Oncology Today—April 14, 2026

This week’s Oncology update highlights regulatory progress, pivotal clinical…

Onco_background

Oncology Today—April 6, 2026

This week’s Oncology update highlights regulatory progress, late-stage clinical…

Onco_background

Oncology Today—March 30, 2026

This week’s Oncology update highlights regulatory momentum, late-stage clinical…

Oncology News

Oncology Video Recap—January 5, 2026

This Oncology video recap covering news from the last thre weeks brings…

Onco_background

Oncology Today — October 20, 2025

Catch the latest Oncology news, featuring ESMO 2025 updates, FDA and EMA…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
LucidWargames
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Iterative Health Acquisition of NextStage Cardiology Research Sites
Lucid Diligence Brief: ERS Genomics and Aurigene CRISPR/Cas9 License
Lucid Diligence Brief: Catalent and Elpida Therapeutics announced a strategic partnership for late-phase AAV manufacturing
Rare Diseases Today—May 14, 2026
Cardiovascular Today—May 14, 2026

Tags

biotech incubator Charles River Chronic disease mortality conduction-system pacing consumer triage AI cost reduction Cytarabine DIPS Arena Eledon Pharmaceuticals Enzalutamide FDA Digital Health Advisory FG001 GLP-1 Receptor Agonists gout flares Hugo RAS Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer Jaypirca live biotherapeutic product Lonza May Health MicroRNAs MIRACLE2 naxtarubicin NCEL-101 NGS OCALIVA Pie Medical Polypill PPMS provider strategy RCT-Twin-GAN Repinatrabit Rinvoq Rituximab Spikevax Stanford Medicine Sutra Medical TG Therapeutics TLR4 TLX591-Tx Transgene TYMLOS UBT251 Ver-A-T1D Zydus

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Iterative Health Acquisition of NextStage Cardiology Research Sites
Lucid Diligence Brief: ERS Genomics and Aurigene CRISPR/Cas9 License
Lucid Diligence Brief: Catalent and Elpida Therapeutics announced a strategic partnership for late-phase AAV manufacturing
Rare Diseases Today—May 14, 2026
Cardiovascular Today—May 14, 2026

TAGS

biotech incubator Charles River Chronic disease mortality conduction-system pacing consumer triage AI cost reduction Cytarabine DIPS Arena Eledon Pharmaceuticals Enzalutamide FDA Digital Health Advisory FG001 GLP-1 Receptor Agonists gout flares Hugo RAS Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer Jaypirca live biotherapeutic product Lonza May Health MicroRNAs MIRACLE2 naxtarubicin NCEL-101 NGS OCALIVA Pie Medical Polypill PPMS provider strategy RCT-Twin-GAN Repinatrabit Rinvoq Rituximab Spikevax Stanford Medicine Sutra Medical TG Therapeutics TLR4 TLX591-Tx Transgene TYMLOS UBT251 Ver-A-T1D Zydus

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy